A nuclear magnetic resonance spectroscopic metabonomics analysis for serum samples of hypertension patients with hyperactivity of liver-yang
- Received Date: 2009-12-03
- Rev Recd Date: 2010-03-15
-
Key words:
- metabonomics /
- nuclear magnetic resonance spectroscopy /
- principal components analysis /
- hypertension /
- syndrome of ascendant hyperactivity of liver yang
Abstract: Objective To apply 1HNMR spectroscopic analysis and principal components analysis(PCA) for investigating the difference of blood composition spectrum between hypertension patients with hyperactivity of liver-yang and healthy volunteers,to search possible biomarker,Reveal the nature of syndrome of hyperactivity of liver-yang. Methods Choose typical cases according to the clinic diagnostic criteria for liver-yang hyperactivity hypertension,and analysis the components in the blood of hypertension in the patients with syndrome of ascendant hyperactivity of liver-yang and healthy volunteers by 1HNMR.Track biomarkers and make the possible explanation of the relevant metabolic pathways with pattern recognition by the PCA method. Results The data from the analysis by PCA of the serum samples of hypertension in hypertension patients with syndrome of ascendant hyperactivity of liver-yang and healthy volunteers shows that: two sets of data can be classified in the score plot.There is significant differences existing between the two groups in terms of relative metabolism of body,especially for some amino acid metabolism and Glucose metabolism. Conclusion The metabonomics method,1HNMR combined with PCA pattern recognition,has advantages in studying pathophysiological changes of the body under the complicated conditions.The study provided evidences for probing the essence of the hypertension of syndrome of ascendant hyperactivity of liver-yang and researching the clinical diagnosis of such diseases.
Citation: | JIANG Hai-qiang, MA Bin, NIE Lei, LI Yun-lun. A nuclear magnetic resonance spectroscopic metabonomics analysis for serum samples of hypertension patients with hyperactivity of liver-yang[J]. Journal of Pharmaceutical Practice and Service, 2010, 28(4): 258-261. |